Triple-Drug attack on liver cancer shows promise in early trial
NCT ID NCT06698250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing whether a combination of three drugs—zanzalintinib, durvalumab, and tremelimumab—can shrink tumors in people with advanced liver cancer that cannot be removed surgically. The study will enroll 40 participants who have not received prior systemic therapy. Researchers aim to find the best dose and measure how many patients respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanzalintinib (XL-092) combined with durvalumab (Imfinzi) and tremelimumab (Imjudo)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong
This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug combination may cause significant side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neal Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mays Cancer Center, UT Health San Antonio
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••